Avantor (AVTR) Stock Overview
Engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
AVTR Community Fair Values
See what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Avantor, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.52 |
| 52 Week High | US$16.05 |
| 52 Week Low | US$7.27 |
| Beta | 0.89 |
| 1 Month Change | 11.17% |
| 3 Month Change | 62.00% |
| 1 Year Change | 24.16% |
| 3 Year Change | -26.48% |
| 5 Year Change | -64.74% |
| Change since IPO | 7.03% |
Recent News & Updates
AVTR: Early Turnaround Progress Will Likely Struggle To Sustain Elevated Earnings Multiple
Analysts have lifted the fair value estimate for Avantor to $12 from $7, reflecting a series of higher Street price targets around $12 to $14 that are tied to recent Q2 earnings beats, early progress under the new CEO, and ongoing self help initiatives. Analyst Commentary Recent research updates on Avantor show a cluster of higher fair value and price targets after the Q2 earnings beat and the early phase of the new CEO's plan.Avantor: Smaller Green Shoots Of Organic Growth Returning Are Well Priced In
Summary Avantor has shown stabilization, with organic growth returning and leverage concerns receding as net debt declines. Avantor raised its full-year organic sales and adjusted earnings guidance, signaling a likely return to positive growth in H2. Margin improvement remains a key lever; every 1% margin gain could add $0.10 per share pre-tax, but topline growth is required. Shares have nearly doubled since April, reflecting improved outlook, but current valuations already price in much of the good news. Read the full article on Seeking AlphaAVTR: Turnaround Progress And Sector Tailwinds Will Likely Define Next Phase
Analysts have lifted the Avantor fair value estimate from $10.31 to $14.56 after a series of price target increases across the Street. This reflects updated views on discount rate, revenue growth, profit margin, and future P/E assumptions following recent Q2 results and turnaround progress.AVTR: Turnaround Execution And Sector Recovery Will Support Future Repricing
Analysts have raised Avantor's fair value estimate from $15.99 to $17.94, reflecting higher price targets across the Street following Q2 results and a management turnaround that is starting to appear in reported margins and growth assumptions. Analyst Commentary Recent Street commentary around Avantor has shifted toward a more constructive tone, with several firms resetting price targets higher following the latest Q2 earnings and early signs of progress under the new leadership team.Recent updates
Shareholder Returns
| AVTR | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 4.8% | 8.8% | 0.5% |
| 1Y | 24.2% | 31.7% | 12.0% |
Return vs Industry: AVTR underperformed the US Life Sciences industry which returned 31.7% over the past year.
Return vs Market: AVTR exceeded the US Market which returned 12% over the past year.
Price Volatility
| AVTR volatility | |
|---|---|
| AVTR Average Weekly Movement | 7.0% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: AVTR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AVTR's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1904 | 13,500 | Emmanuel Ligner | www.avantorsciences.com |
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies.
Avantor, Inc. Fundamentals Summary
| AVTR fundamental statistics | |
|---|---|
| Market cap | US$10.73b |
| Earnings (TTM) | -US$578.00m |
| Revenue (TTM) | US$6.56b |
Is AVTR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVTR income statement (TTM) | |
|---|---|
| Revenue | US$6.56b |
| Cost of Revenue | US$4.47b |
| Gross Profit | US$2.09b |
| Other Expenses | US$2.67b |
| Earnings | -US$578.00m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.85 |
| Gross Margin | 31.83% |
| Net Profit Margin | -8.81% |
| Debt/Equity Ratio | 65.2% |
How did AVTR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/18 21:49 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Avantor, Inc. is covered by 30 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Bamberger | Baird |
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |